Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ridgway, G. L.
Right arrow Articles by Felmingham, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ridgway, G. L.
Right arrow Articles by Felmingham, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 40, 31-34, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp

GL Ridgway, H Salman, MJ Robbins, C Dencer and D Felmingham
Department of Clinical Microbiology, University College London Hospitals, UK.

The activity of grepafloxacin, a new orally active fluoroquinolone, was compared with the activities of ofloxacin, clarithromycin and doxycycline against Chlamydia pneumoniae, Chlamydia trachomatis, Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum, and with the activities of ofloxacin, clarithromycin and rifampicin against Legionella spp. Grepafloxacin (MIC range 0.06-0.12 mg/L) was some 8-16 times more active than ofloxacin against the chlamydiae, showing activity similar to that of doxycycline, and equal or two- to four-fold less active than clarithromycin. Grepafloxacin was four-fold more active than ofloxacin against M. pneumoniae (MIC 0.06-0.5 mg/L) and U. urealyticum (MIC 0.12-1.0 mg/L), but 16 times more active against M. hominis (MIC 0.015-0.05 mg/L). Grepafloxacin was highly active against Legionella spp. (MIC 0.008-0.03 mg/L), showing equivalent activity to ofloxacin, clarithromycin and rifampicin.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
H. Takemura, H. Yamamoto, H. Kunishima, H. Ikejima, T. Hara, K. Kanemitsu, S. Terakubo, Y. Shoji, M. Kaku, and J. Shimada
Evaluation of a human monocytic cell line THP-1 model for assay of the intracellular activities of antimicrobial agents against Legionella pneumophila
J. Antimicrob. Chemother., October 1, 2000; 46(4): 589 - 594.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. M. Bebear, H. Renaudin, A. Bryskier, and C. Bebear
Comparative Activities of Telithromycin (HMR 3647), Levofloxacin, and Other Antimicrobial Agents against Human Mycoplasmas
Antimicrob. Agents Chemother., July 1, 2000; 44(7): 1980 - 1982.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
M. Dedicoat and P. Venkatesan
The treatment of Legionnaires' disease
J. Antimicrob. Chemother., June 1, 1999; 43(6): 747 - 752.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. M. Bebear, H. Renaudin, T. Schaeverbeke, F. Leblanc, and C. Bebear
In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas
J. Antimicrob. Chemother., May 1, 1999; 43(5): 711 - 714.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
New fluoroquinolone antibiotics
DTB, January 1, 1999; 37(1): 6 - 8.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.